<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33871026</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1214</StartPage><EndPage>1229</EndPage><MedlinePgn>1214-1229</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab018</ELocationID><Abstract><AbstractText>Knowledge about converging disease mechanisms in the heterogeneous syndrome amyotrophic lateral sclerosis (ALS) is rare, but may lead to therapies effective in most ALS cases. Previously, we identified serum microRNAs downregulated in familial ALS, the majority of sporadic ALS patients, but also in presymptomatic mutation carriers. A 5-nucleotide sequence motif (GDCGG; D&#x2009;=&#x2009;G, A or U) was strongly enriched in these ALS-related microRNAs. We hypothesized that deregulation of protein(s) binding predominantly to this consensus motif was responsible for the ALS-linked microRNA fingerprint. Using microRNA pull-down assays combined with mass spectrometry followed by extensive biochemical validation, all members of the fragile X protein family, FMR1, FXR1 and FXR2, were identified to directly and predominantly interact with GDCGG microRNAs through their structurally disordered RGG/RG domains. Preferential association of this protein family with ALS-related microRNAs was confirmed by in vitro binding studies on a transcriptome-wide scale. Immunohistochemistry of lumbar spinal cord revealed aberrant expression level and aggregation of FXR1 and FXR2 in C9orf72- and FUS-linked familial ALS, but also patients with sporadic ALS. Further analysis of ALS autopsies and induced pluripotent stem cell-derived motor neurons with FUS mutations showed co-aggregation of FXR1 with FUS. Hence, our translational approach was able to take advantage of blood microRNAs to reveal CNS pathology, and suggests an involvement of the fragile X-related proteins in familial and sporadic ALS already at a presymptomatic stage. The findings may uncover disease mechanisms relevant to many patients with ALS. They furthermore underscore the systemic, extra-CNS aspect of ALS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freischmidt</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center For Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Anand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limm</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimyanin</LastName><ForeName>Vitaly L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technical University Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demestre</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gla&#xdf;</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holzmann</LastName><ForeName>Karlheinz</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Core Unit Genomics, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helferich</LastName><ForeName>Anika M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brockmann</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamoah</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poser</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oefner</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;ckers</LastName><ForeName>Tobias M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>German Center For Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center For Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technical University Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weis</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinders</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danzer</LastName><ForeName>Karin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division for Neurodegenerative Diseases, Neurology Department, University Medicine Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497683">FMR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C096916">FXR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>139135-51-6</RegistryNumber><NameOfSubstance UI="D051860">Fragile X Mental Retardation Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051860" MajorTopicYN="N">Fragile X Mental Retardation Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FMR1/FMRP</Keyword><Keyword MajorTopicYN="N">FXR1</Keyword><Keyword MajorTopicYN="N">FXR2</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>19</Day><Hour>8</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33871026</ArticleId><ArticleId IdType="pmc">PMC8105042</ArticleId><ArticleId IdType="doi">10.1093/brain/awab018</ArticleId><ArticleId IdType="pii">6237184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH.. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124:339-352.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A.. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162-172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al.Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt JH, Hyman T, Dikic I.. Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia. Trends Mol Med. 2016;22:769-783.</Citation><ArticleIdList><ArticleId IdType="pubmed">27498188</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Koppers M, Groen EJ, et al.Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. Acta Neuropathol. 2016;132:175-196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947123</ArticleId><ArticleId IdType="pubmed">27164932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y, Kuo SW, Chen L, Heckman CJ, Jiang MC.. The essential and downstream common proteins of amyotrophic lateral sclerosis: A protein-protein interaction network analysis. PLoS One. 2017;12:e0172246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5345759</ArticleId><ArticleId IdType="pubmed">28282387</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Muller K, Zondler L, et al.Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014;137:2938-2950.</Citation><ArticleIdList><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Muller K, Zondler L, et al.Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:2660.e15-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26142125</ArticleId></ArticleIdList></Reference><Reference><Citation>Turchinovich A, Weiz L, Burwinkel B.. Extracellular miRNAs: The mystery of their origin and function. Trends Biochem Sci. 2012;37:460-465.</Citation><ArticleIdList><ArticleId IdType="pubmed">22944280</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, Muller K, Khalaji S, et al.Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132:391-411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA.. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615629</ArticleId><ArticleId IdType="pubmed">19033363</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA.. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Walia RR, Xue LC, Wilkins K, El-Manzalawy Y, Dobbs D, Honavar V.. RNABindRPlus: A predictor that combines machine learning and sequence homology-based methods to improve the reliability of predicted RNA-binding residues in proteins. PLoS One. 2014;9:e97725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028231</ArticleId><ArticleId IdType="pubmed">24846307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Xie Y, Ma J, et al.IBS: An illustrator for the presentation and visualization of biological sequences. Bioinformatics. 2015;31:3359-3361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595897</ArticleId><ArticleId IdType="pubmed">26069263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturn A, Quackenbush J, Trajanoski Z.. Genesis: Cluster analysis of microarray data. Bioinformatics. 2002;18:207-208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11836235</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Pal A, Goswami A, et al.Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nat Commun. 2018;9:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780468</ArticleId><ArticleId IdType="pubmed">29362359</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitiprolu M, Jagow C, Tremblay V, et al.A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat Commun. 2018;9:2794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052026</ArticleId><ArticleId IdType="pubmed">30022074</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J, Demestre M, Putz S, et al.FUS mislocalization and vulnerability to DNA damage in ALS patients derived hiPSCs and aging motoneurons. Front Cell Neurosci. 2016;10:290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5183648</ArticleId><ArticleId IdType="pubmed">28082870</ArticleId></ArticleIdList></Reference><Reference><Citation>Japtok J, Lojewski X, Naumann M, et al.Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging. Neurobiol Dis. 2015;82:420-429.</Citation><ArticleIdList><ArticleId IdType="pubmed">26253605</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y.. Controlling the false discovery rate&#x2014;A practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.</Citation></Reference><Reference><Citation>Tsui NB, Ng EK, Lo YM.. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002;48:1647-1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12324479</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy BA, Gonzales AD, Perkins J, et al.Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J Proteome Res. 2004;3:1120-1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">15595720</ArticleId></ArticleIdList></Reference><Reference><Citation>Blice-Baum AC, Mihailescu MR.. Biophysical characterization of G-quadruplex forming FMR1 mRNA and of its interactions with different fragile X mental retardation protein isoforms. RNA. 2014;20:103-114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866639</ArticleId><ArticleId IdType="pubmed">24249225</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell JC, Fraser CE, Mostovetsky O, Darnell RB.. Discrimination of common and unique RNA-binding activities among Fragile X mental retardation protein paralogs. Hum Mol Genet. 2009;18:3164-3177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722981</ArticleId><ArticleId IdType="pubmed">19487368</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan AT, Kuryavyi V, Darnell JC, et al.Structure-function studies of FMRP RGG peptide recognition of an RNA duplex-quadruplex junction. Nat Struct Mol Biol. 2011;18:796-804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130835</ArticleId><ArticleId IdType="pubmed">21642970</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhl JA, Chopra P, Anderson BR, Bassell GJ, Warren ST.. Analysis of FMRP mRNA target datasets reveals highly associated mRNAs mediated by G-quadruplex structures formed via clustered WGGA sequences. Hum Mol Genet. 2014;23:5479-5491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4168832</ArticleId><ArticleId IdType="pubmed">24876161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilyev N, Polonskaia A, Darnell JC, Darnell RB, Patel DJ, Serganov A.. Crystal structure reveals specific recognition of a G-quadruplex RNA by a beta-turn in the RGG motif of FMRP. Proc Natl Acad Sci USA. 2015;112:E5391-E5400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593078</ArticleId><ArticleId IdType="pubmed">26374839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fay MM, Lyons SM, Ivanov P.. RNA G-quadruplexes in biology: Principles and molecular mechanisms. J Mol Biol. 2017;429:2127-2147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5603239</ArticleId><ArticleId IdType="pubmed">28554731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane AN, Chaires JB, Gray RD, Trent JO.. Stability and kinetics of G-quadruplex structures. Nucleic Acids Res. 2008;36:5482-5515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553573</ArticleId><ArticleId IdType="pubmed">18718931</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson BR, Chopra P, Suhl JA, Warren ST, Bassell GJ.. Identification of consensus binding sites clarifies FMRP binding determinants. Nucleic Acids Res. 2016;44:6649-6659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001617</ArticleId><ArticleId IdType="pubmed">27378784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascano M Jr., Mukherjee N, Bandaru P, et al.FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. 2012;492:382-386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528815</ArticleId><ArticleId IdType="pubmed">23235829</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Ge W.. The tandem Agenet domain of fragile X mental retardation protein interacts with FUS. Sci Rep. 2017;7:962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430443</ArticleId><ArticleId IdType="pubmed">28424484</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, et al.A liquid-to-solid phase transition of the ALS Protein FUS accelerated by disease mutation. Cell. 2015;162:1066-1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Yamada SB, Siddegowda BB, et al.Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation. Hum Mol Genet. 2015;24:6886-6898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007633</ArticleId><ArticleId IdType="pubmed">26385636</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A, Eitan C, Liou LL, et al.Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: A new mechanism for ALS. EMBO J. 2015;34:2633-2651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttlin EL, Bruckner RJ, Paulo JA, et al.Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545:505-509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5531611</ArticleId><ArticleId IdType="pubmed">28514442</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttlin EL, Ting L, Bruckner RJ, et al.The BioPlex Network: A systematic exploration of the human interactome. Cell. 2015;162:425-440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617211</ArticleId><ArticleId IdType="pubmed">26186194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, O'Connor JP, Siomi MC, et al.The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J. 1995;14:5358-5366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394645</ArticleId><ArticleId IdType="pubmed">7489725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Lemay N, Ko HK, et al.Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet. 2010;19:4160-4175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Serrano A, Gerbino V, et al.Nuclear accumulation of mRNAs underlies G4C2-repeat-induced translational repression in a cellular model of C9orf72 ALS. J Cell Sci. 2015;128:1787-1799.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788698</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Hur J, Lunn JS, et al.Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell Neurosci. 2016;71:34-45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig N, Leidinger P, Becker K, et al.Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44:3865-3877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4856985</ArticleId><ArticleId IdType="pubmed">26921406</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Ifrim MF, Valdez AN, Raj N, Bassell GJ.. Aberrant RNA translation in fragile X syndrome: From FMRP mechanisms to emerging therapeutic strategies. Brain Res. 2018;1693:24-36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377270</ArticleId><ArticleId IdType="pubmed">29653083</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheever A, Ceman S.. Translation regulation of mRNAs by the fragile X family of proteins through the microRNA pathway. RNA Biol. 2009;6:175-178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4337776</ArticleId><ArticleId IdType="pubmed">19276651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Zarnescu DC, Ceman S, et al.Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004;7:113-117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14703574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zealy RW, Wrenn SP, Davila S, Min KW, Yoon JH.. microRNA-binding proteins: Specificity and function. Wiley Interdiscip Rev RNA. 2017;8:e1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">28130820</ArticleId></ArticleIdList></Reference><Reference><Citation>Schopp IM, Amaya Ramirez CC, Debeljak J, et al.Split-BioID a conditional proteomics approach to monitor the composition of spatiotemporally defined protein complexes. Nat Commun. 2017;8:15690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467174</ArticleId><ArticleId IdType="pubmed">28585547</ArticleId></ArticleIdList></Reference><Reference><Citation>Treiber T, Treiber N, Plessmann U, et al.A compendium of RNA-binding proteins that regulate microRNA biogenesis. Mol Cell. 2017;66:270-284.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">28431233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan RP, Zhou LT, Yang HX, et al.Involvement of FMRP in primary MicroRNA processing via enhancing Drosha translation. Mol Neurobiol. 2017;54:2585-2594.</Citation><ArticleIdList><ArticleId IdType="pubmed">26993298</ArticleId></ArticleIdList></Reference><Reference><Citation>Haramati S, Chapnik E, Sztainberg Y, et al.miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA. 2010;107:13111-13116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919953</ArticleId><ArticleId IdType="pubmed">20616011</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Fumagalli L, Prior R, Van Den Bosch L.. Current advances and limitations in modeling ALS/FTD in a dish using induced pluripotent stem cells. Front Neurosci. 2017;11:671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733489</ArticleId><ArticleId IdType="pubmed">29326542</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>